---
title: "Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286891476.md"
description: "Entrada Therapeutics updated its corporate presentation, highlighting favorable safety and significant functional gains in ENTR-601-44 Cohort 1 for DMD. Cohort 2 data is expected by year-end 2026, with ongoing dosing. The company anticipates multiple catalysts in 2026 and has a cash runway into Q3 2027."
datetime: "2026-05-19T10:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286891476.md)
  - [en](https://longbridge.com/en/news/286891476.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286891476.md)
---

# Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026

**Entrada Therapeutics reported favorable ENTR-601-44 Cohort 1 safety and statistically significant Time to Rise velocity improvement, and expects additional cohort and program readouts through year-end 2026.**

**Key Highlights:**

-   Updated corporate presentation furnished as Exhibit 99.1 under Regulation FD for investor meetings.
-   ENTR-601-44 Cohort 1: 6 mg/kg showed favorable safety, no SAEs, renal markers comparable to placebo.
-   Cohort 1 demonstrated statistically significant improvement in Time to Rise and Time to Rise velocity vs placebo.
-   Cohort 2 (12 mg/kg) dosing ongoing with Cohort 2 dystrophin and functional data expected by year-end 2026.
-   ENTR-601-45 Cohort 1 data expected mid-2026; multiple DMD, DM1 and IRD catalysts planned in 2026; cash runway into Q3 2027.

Original SEC Filing: Entrada Therapeutics, Inc. \[ TRDA \] - 8-K - May. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TRDA.US](https://longbridge.com/en/quote/TRDA.US.md)

## Related News & Research

- [Entrada Therapeutics Highlights Transformational Year and Pipeline Progress](https://longbridge.com/en/news/286898145.md)
- [22:30 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA](https://longbridge.com/en/news/286497157.md)
- [ASP Releases Updated Investor Presentation, Notes Forward-Looking Statements](https://longbridge.com/en/news/287122849.md)
- [Federal Signal posts May 2026 investor presentation, raises 2026 outlook and margin targets](https://longbridge.com/en/news/287104853.md)
- [Athene posts fixed-income investor presentation for May 15, 2025 call](https://longbridge.com/en/news/286560329.md)